Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.

Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.

Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.

Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.

Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.

Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.

Abstract: Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a MHC molecule including covalently linked first and second domains, wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain, wherein the amino terminus of the ?1 domain is covalently linked to the carboxy terminus of the ?1 domain, and a prostate specific antigen peptide covalently linked to the first domain. The methods include administering a disclosed MHC molecule to a subject with prostate cancer.

Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.

Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.

Abstract: Disclosed herein are isolated major histocompatibility complex (MHC) class II ?1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II ?1 domain polypeptide (or portion thereof) and does not include an MHC class II ?2, ?1, or ?2 domain. The disclosed MHC class II ?1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II ?1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II ?1 domain and ?1 domain (such as a ?1?1 RTL).